Test Catalog

Test ID: EGFRD    
Cell-Free DNA EGFR Exon 18, 19, 20, 21, Mutation Analysis, Blood

Useful For Suggests clinical disorders or settings where the test may be helpful

As an alternative to invasive tissue biopsies for the determination of EGFR-mutation status

 

Selection of patients with non-small cell lung cancer who are most likely to benefit from targeted therapies

Genetics Test Information Provides information that may help with selection of the correct genetic test or proper submission of the test request

This test evaluates cell-free DNA (cfDNA) in the peripheral blood for the presence of common EGFR mutations in exons 18, 19, 20, and 21 in patients with non-small cell lung cancer and can be used to assess eligibility for targeted therapies. Current data suggests that the efficacy of EGFR-targeted therapy in non-small cell lung cancer patients is limited to patients whose tumors harbor mutations in the EGFR gene.

 

This test is not validated for serial monitoring of patients with cancer. This test is also not intended as a screening test to identify cancer.

Method Name A short description of the method used to perform the test

Quantitative Polymerase Chain Reaction (PCR) Analysis

NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.

No

Reporting Name Lists a shorter or abbreviated version of the Published Name for a test

cfDNA EGFR Mutation Analysis, Blood

Aliases Lists additional common names for a test, as an aid in searching

NSCLC
Non-small cell lung cancer
Lung cancer
EGFR
Epidermal growth factor receptor
Cell free DNA
cfDNA
Cell-free DNA
Circulating tumor DNA
Liquid biopsy
Circulating tumor cells
T790M
EGFRD